Citizens Reiterates Market Outperform on Lyell Immunopharma, Maintains $34 Price Target
Benzinga Newsdesk 4 months ago
NewsPrice TargetReiterationAnalyst Ratings
Citizens analyst Reni J. Benjamin reiterates Lyell Immunopharma (NASDAQ:LYEL) with a Market Outperform and maintains $34 price target.
Citizens analyst Reni J. Benjamin reiterates Lyell Immunopharma (NASDAQ:LYEL) with a Market Outperform and maintains $34 price target.